

# Eduard Bentea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8391230/publications.pdf>

Version: 2024-02-01

33  
papers

698  
citations

516710

16  
h-index

580821

25  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1285  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Proteasome Inhibition Model of Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 31-63.	2.8	81
2	The cystine-glutamate exchanger (xCT, Slc7a11) is expressed in significant concentrations in a subpopulation of astrocytes in the mouse brain. Glia, 2018, 66, 951-970.	4.9	64
3	Measurement of lactate levels in postmortem brain, iPSCs, and animal models of schizophrenia. Scientific Reports, 2019, 9, 5087.	3.3	44
4	Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated $\alpha$ -synuclein. Frontiers in Behavioral Neuroscience, 2015, 9, 68.	2.0	41
5	Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed. Journal of Comparative Neurology, 2016, 524, 1015-1032.	1.6	34
6	Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments. Molecular Neurobiology, 2019, 56, 4492-4517.	4.0	34
7	Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. Molecular Omics, 2019, 15, 173-188.	2.8	33
8	Disruption of the HPA-axis through corticosterone-release pellets induces robust depressive-like behavior and reduced BDNF levels in mice. Neuroscience Letters, 2016, 626, 119-125.	2.1	30
9	In-depth behavioral characterization of the corticosterone mouse model and the critical involvement of housing conditions. Physiology and Behavior, 2016, 156, 199-207.	2.1	29
10	Absence of system xc <sup>-</sup> in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 49-58.	4.8	28
11	Genetic deletion of xCT attenuates peripheral and central inflammation and mitigates LPS-induced sickness and depressive-like behavior in mice. Glia, 2018, 66, 1845-1861.	4.9	27
12	Corticostriatal dysfunction and social interaction deficits in mice lacking the cystine/glutamate antiporter. Molecular Psychiatry, 2020, 26, 4754-4769.	7.9	27
13	Altered vesicular glutamate transporter expression in human temporal lobe epilepsy with hippocampal sclerosis. Neuroscience Letters, 2015, 590, 184-188.	2.1	26
14	Alterations in the motor cortical and striatal glutamatergic system and d-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease. Neurochemistry International, 2015, 88, 88-96.	3.8	24
15	Validation of the 6Hz refractory seizure mouse model for intracerebroventricularly administered compounds. Epilepsy Research, 2015, 115, 67-72.	1.6	23
16	Absence of system xc <sup>-</sup> on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis. Journal of Neuroinflammation, 2017, 14, 9.	7.2	20
17	Anticonvulsant and antiepileptogenic effects of system xc <sup>-</sup> inactivation in chronic epilepsy models. Epilepsia, 2019, 60, 1412-1423.	5.1	20
18	NMDA receptor antagonism potentiates the l-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats. Neuropharmacology, 2014, 85, 198-205.	4.1	14

#	ARTICLE	IF	CITATIONS
19	MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT. <i>Neuroscience Letters</i> , 2015, 593, 1-6.	2.1	14
20	Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 26-32.	2.2	12
21	Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc <sup>-</sup> . <i>Experimental Neurology</i> , 2017, 290, 15-28.	4.1	10
22	Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson's disease. <i>Brain Research Bulletin</i> , 2017, 130, 257-267.	3.0	8
23	KRSA: An R package and R Shiny web application for an end-to-end upstream kinase analysis of kinome array data. <i>PLoS ONE</i> , 2021, 16, e0260440.	2.5	8
24	Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor. <i>International Journal of Molecular Sciences</i> , 2017, 18, 558.	4.1	7
25	Acute versus long-term effects of 6-hydroxydopamine on oxidative stress and dopamine depletion in the striatum of mice. <i>Journal of Neuroscience Methods</i> , 2011, 202, 128-136.	2.5	6
26	Slc7a11 (xCT) protein expression is not altered in the depressed brain and system xc <sup>-</sup> deficiency does not affect depression-associated behaviour in the corticosterone mouse model. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 381-392.	2.6	6
27	Lifespan extension with preservation of hippocampal function in aged system xc <sup>-</sup> -deficient male mice. <i>Molecular Psychiatry</i> , 2022, 27, 2355-2368.	7.9	6
28	Aged xCT-Deficient Mice Are Less Susceptible for Lactacystin-, but Not 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-, Induced Degeneration of the Nigrostriatal Pathway. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 796635.	3.7	4
29	Lack of effect of Theiler's murine encephalomyelitis virus infection on system xc <sup>-</sup> . <i>Neuroscience Letters</i> , 2015, 593, 124-128.	2.1	3
30	Selective changes in locomotor activity in mice due to low-intensity microwaves amplitude modulated in the EEG spectral domain. <i>Neuroscience</i> , 2017, 359, 40-48.	2.3	3
31	Chronic Sulfasalazine Treatment in Mice Induces System xc <sup>-</sup> - Independent Adverse Effects. <i>Frontiers in Pharmacology</i> , 2021, 12, 625699.	3.5	3
32	Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 219.	2.0	1
33	T84. Characterizing Signal Transduction Networks in Postmortem Depressed-Suicide Subjects. <i>Biological Psychiatry</i> , 2019, 85, S161.	1.3	0